Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.
Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.
Journey Medical Corporation (DERM)/b) will participate in two investor conferences in September 2026.Co-Founder, President and CEO Claude Maraoui is scheduled for the Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference on Thursday, September 10, 2026, in New York City in a 1x1 meetings format. He is also scheduled for the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 10:00 a.m. ET, also in New York City, featuring a presentation and 1x1 meetings.
A webcast of the H.C. Wainwright presentation will be available on the News and Events page of the Investors section of Journey Medical’s website for approximately 30 days after the meeting.
Longeveron (NASDAQ: LGVN) appointed Nirav Jhaveri, CFA, as Chief Financial Officer, principal financial officer and principal accounting officer, joining the executive leadership team and succeeding Marie Washburn, who returns to her prior role as Corporate Controller.
According to Longeveron, Jhaveri brings over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector and prior CFO roles at Opus Genetics (Nasdaq: IRD), Insilico Medicine (HKEX: 3696.HK) and Journey Medical (Nasdaq: DERM). The company also highlighted ongoing development of its stem cell therapy laromestrocel, with top-line data from a Phase 2b trial in HLHS expected in September 2026.
Journey Medical (Nasdaq: DERM) reported second quarter 2026 total revenue of $18.5 million, up 23% from $15.0 million a year earlier, driven by Emrosi® revenue of $8.1 million. Gross margin was 67%, unchanged year over year, and selling, general and administrative expenses declined to $10.9 million, down $1.0 million.
GAAP net loss narrowed to $0.3 million, or $(0.01) per share, versus a $3.8 million loss, or $(0.16) per share, in 2025. Non-GAAP Adjusted EBITDA turned positive at $2.9 million for the quarter. Cash and cash equivalents were $25.6 million at June 30, 2026, compared with $24.1 million at year-end 2025. Emrosi® total prescriptions reached about 36,000 in Q2 2026, versus 30,000 in Q1 2026.
Journey Medical (Nasdaq: DERM) will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.
U.S. participants can dial 1-866-777-2509, international participants 1-412-317-5413, or register online to receive dial-in details. The webcast will be available via the Investors section of Journey Medical’s website and remain accessible for approximately 30 days after the call.
Journey Medical (Nasdaq: DERM) announced that Co-Founder, President and CEO Claude Maraoui will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference on May 20, 2026. The virtual session is scheduled for 5:00 p.m. ET, with registration via the A.G.P. conference link.
Journey Medical (Nasdaq: DERM) reported first quarter 2026 revenue of $16.0 million, up 21% year-over-year. Emrosi® revenue rose to $6.3 million. Gross margin was 61.0%, including a $1.3 million non-recurring non-cash inventory write-down.
Net loss narrowed to $2.2 million, while Adjusted EBITDA turned positive at $0.6 million. Cash and equivalents increased to $27.2 million. Emrosi® prescriptions reached 29,968, and a new GPO contract expands access to about 85% of U.S. commercial lives.
Journey Medical (Nasdaq: DERM) will release first quarter 2026 financial results after U.S. markets close on Wednesday, May 13, 2026.
Management will host a conference call and audio webcast on May 13, 2026 at 4:30 p.m. ET. Domestic dial-in is 1-866-777-2509; international dial-in is 1-412-317-5413. Registration is available at the provided URL and a replay will be available for ~30 days.
Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.
Approximately 85% of U.S. commercial lives now have access after contracting with a third major GPO. The company expects expanded access to support prescription growth and improved brand profitability as formulary adoption progresses through 2026.
Journey Medical (Nasdaq: DERM) reported full-year 2025 results and corporate highlights on March 25, 2026. Total revenues were $61.9 million, up 10% from $56.1 million in 2024, driven by the commercial launch of Emrosi™ (net revenues $14.7 million; ~53,000 prescriptions).
Gross margin improved to 66.2%, Adjusted EBITDA was $2.9 million, cash was approximately $24.1 million, and working capital was $29.4 million. Net loss narrowed to $11.4 million (−$0.47/share).
Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.
The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET; registration is available online and the replay will remain available about 30 days.